NAC Eye Drops for Fuchs' Dystrophy

This trial tests eye drops containing N-acetyl cysteine (NAC) to determine their effectiveness in protecting and improving eye health in individuals with Fuchs' Dystrophy, a condition affecting the cornea that can lead to vision problems. The researchers aim to discover if the eye drops can reduce oxidative stress, potentially aiding corneal healing. Participants will receive either a 10% or 20% NAC solution or a placebo. Suitable candidates have advanced Fuchs' Dystrophy and cataracts affecting their vision and are scheduled for specific eye surgery. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

You may need to stop using certain eye medications, except for lubricants, hyperosmotic agents, or ocular hypotensive agents. If you're using N-Acetylcysteine in any form, you'll need to stop at least 30 days before joining the trial.

Research has shown that N-acetyl cysteine (NAC) eye drops, in both 10% and 20% strengths, are generally safe and well-tolerated. Studies have found that NAC is often used in eye treatments for conditions like dry eye and meibomian gland dysfunction, with a good safety record. Although specific safety data for these solutions in Fuchs' Dystrophy is lacking, NAC's broader use in eye care suggests it is safe for most people. No major reports of side effects have emerged in these cases, offering reassurance to potential trial participants.¹²³⁴⁵

Researchers are excited about NAC eye drops for Fuchs' Dystrophy because they offer a novel approach by using N-acetyl cysteine (NAC), an antioxidant that targets oxidative stress, a key factor in the progression of this condition. Unlike traditional treatments which mainly focus on managing symptoms, NAC eye drops aim to address the underlying oxidative damage to corneal cells. With concentrations of 10% and 20% being tested, this treatment could provide a more effective and direct method to protect and potentially restore corneal health. Additionally, NAC is well-tolerated and has been used in other eye conditions, making it a promising candidate for improving outcomes in Fuchs' Dystrophy.

Research has shown that N-acetyl cysteine (NAC) eye drops protect eye cells by reducing damage from harmful molecules, known as oxidative stress. Studies have found that NAC improves the survival of corneal endothelial cells, which are crucial for clear vision. This is particularly beneficial for conditions like Fuchs' Dystrophy, where these cells are at risk. In this trial, researchers are testing both 10% and 20% NAC eye drop solutions in separate treatment arms for their protective effects. Early results suggest that these drops are well-tolerated and may improve eye health by managing oxidative stress.¹²³⁵⁶